Schiffrin EL, Pu Q, Park JB. Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertension patients[J]. Am J Hypertens, 2002, 15(2 Pt 1): 105-110.
[2]
Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function[J]. J Hypertens, 2002, 20(1): 71-78.
[3]
Ferguson JM, Lustermans FA, Breed JG, et al. The influence of perindopril and the diuretic combination amiloride+hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients[J]. J Hypertens, 1995, 13(8): 839-848.
Lchihara A, Hayashi M, Kaneshiro Y, et al. Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients[J]. Am J Kidney Dis, 2005, 45(5): 866-874.
[7]
Ferguson JM, Minas J, Siapantas S, et al. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension[J]. J Cardiovasc Pharmacol, 2008, 51(6): 590-595.
[8]
Simon AC, Levenson JA, Safar AM, et al. ACE inhibition and brachial artery haemodynamics in hypertension[J].Br J Clin Pharmacol, 1984, 18(Suppl 2): 243-247.
[9]
Zou Z, Xi GL, Yuan HB, et al. Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials[J]. J Hum Hypertens, 2009, 23(5): 339-349.
[10]
Wang JG, Staessen JA, Li Y, et al. Carotid intima-media thicknedd and antihypertensive treatment: a meta-analysis of randomized controlled trials[J]. Stroke, 2006, 37(7): 1933-1940.
Dahl？f B, Devereux RB, Kjeldsen SE, et al. Cardiovascular mobidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol[J]. Lancet, 2002, 359(9311): 995-1003.
[13]
Dahl？f B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen ofamlodipine adding perindopril as required versus atenolol addingbendroflumethiazide as required, in the Anglo-Scandinavian Cardiac OutcomesTrial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial [J]. Lancet, 2005, 366(9489): 895-906.
[14]
Bradley HA, Wiysonge CS, Volmink JA. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension？ Systematic review and meta-analysis[J]. Hypertension, 2006, 24(11): 2131-2141.
[15]
Lindholm LH, Carlberg B, Samuelsson O. Should βblockers remain first choice in the treatment of primary hypertension A meta-analysis[J]. Lancet, 2005, 366(9496): 1545-1553.
[ 2 ] Tao J, Jin Y, Wang L, et al. In vivo adaptive response of the peripheral conduit artery in patients with borderline systolic hypertension[J]. Chin Med J, 2003, 116(3): 333-336.
[ 4 ] Mackenzie IS, McEniery CM, Dhakam Z, et al.Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension[J]. Hypertension, 2009, 54(2): 409-413.
[20]
[ 5 ] Gasowski J, Fagard RH, Staessen JA, et al. Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups [J]. J Hypertens, 2002, 20(1): 145-151.
[21]
[ 6 ] Strbova J, Kmecova J, Klimas J. Elevated pulse pressure in treated hypertensive patients during 24-hour ambulatory blood pressure monitoring[J]. Bratisl Lek Listy, 2011, 112(10): 562-567.
[ 8 ] Lee SW, Hai JJ, Kong SL, et al. Side differences of carotid intima-media thickness in predicting cardiovascular events among patients with coronary artery disease[J]. Angiology, 2011, 62(3): 231-236.
[24]
[ 9 ] Cohn JN, Finkelstein S, McVeigh G, et al. Noninvasive pulse wave analysis for the early detection of the vascular disease[J]. Hypertension, 1995, 26(3): 503-508.
[25]
Gupta V, Sachdeva S, Khan AS, et al. Endothelial dysfunction and inflammation in different stages of essential hypertension[J].Saudi J Kidney Dis Transpl, 2011, 22(1): 97-103.
Marchesi C, Paradis P, Schiffrin EL. Role of the rennin-angiotension system in vascular inflammation[J]. Trends pharmacol Sci, 2008, 29(7): 367-374.
[28]
Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk[J]. Lancet, 2007, 369(9568): 1208-1219.
[29]
Marketou ME, Kontaraki JE, Tsakountakis NA, et al. Differential effect of telmisartan and amlodipine on monoctyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension[J]. Am J Cardiol, 2011, 107(1): 59-63.
[30]
Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension[J].Am J Hypertens, 2005, 18(1): 50-55.
